Gilead Sciences Price to Book Ratio 2010-2022 | GILD
Historical price to book ratio values for Gilead Sciences (GILD) over the last 10 years. The current price to book ratio for Gilead Sciences as of January 27, 2023 is 4.98.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Gilead Sciences Price/Book Ratio Historical Data |
| Date |
Stock Price |
Book Value per Share |
Price to Book Ratio |
| 2023-01-27 |
83.73 |
|
4.99 |
| 2022-09-30 |
61.18 |
$16.79 |
3.64 |
| 2022-06-30 |
60.62 |
$16.12 |
3.76 |
| 2022-03-31 |
57.58 |
$15.87 |
3.63 |
| 2021-12-31 |
69.46 |
$16.80 |
4.13 |
| 2021-09-30 |
66.15 |
$17.11 |
3.87 |
| 2021-06-30 |
64.56 |
$15.72 |
4.11 |
| 2021-03-31 |
59.97 |
$15.12 |
3.97 |
| 2020-12-31 |
53.44 |
$14.53 |
3.68 |
| 2020-09-30 |
57.32 |
$13.94 |
4.11 |
| 2020-06-30 |
69.08 |
$14.47 |
4.77 |
| 2020-03-31 |
66.50 |
$17.69 |
3.76 |
| 2019-12-31 |
57.23 |
$17.89 |
3.20 |
| 2019-09-30 |
55.31 |
$16.38 |
3.38 |
| 2019-06-30 |
58.40 |
$17.96 |
3.25 |
| 2019-03-31 |
55.68 |
$17.34 |
3.21 |
| 2018-12-31 |
53.05 |
$16.80 |
3.16 |
| 2018-09-30 |
64.94 |
$17.78 |
3.65 |
| 2018-06-30 |
59.13 |
$16.77 |
3.53 |
| 2018-03-31 |
62.42 |
$15.89 |
3.93 |
| 2017-12-31 |
58.90 |
$15.67 |
3.76 |
| 2017-09-30 |
66.14 |
$19.32 |
3.42 |
| 2017-03-31 |
54.66 |
$16.00 |
3.42 |
| 2016-12-31 |
57.19 |
$14.78 |
3.87 |
| 2016-09-30 |
62.80 |
$13.13 |
4.78 |
| 2016-06-30 |
65.81 |
$12.11 |
5.44 |
| 2016-03-31 |
72.07 |
$10.40 |
6.93 |
| 2015-12-31 |
79.01 |
$13.44 |
5.88 |
| 2015-09-30 |
76.15 |
$12.38 |
6.15 |
| 2015-06-30 |
90.67 |
$11.29 |
8.03 |
| 2015-03-31 |
75.72 |
$11.91 |
6.36 |
| 2014-12-31 |
72.73 |
$10.55 |
6.89 |
| 2014-09-30 |
82.14 |
$9.16 |
8.97 |
| 2014-06-30 |
63.97 |
$10.77 |
5.94 |
| 2014-03-31 |
54.68 |
$8.91 |
6.14 |
| 2013-12-31 |
57.95 |
$7.66 |
7.57 |
| 2013-09-30 |
48.51 |
$7.30 |
6.65 |
| 2013-06-30 |
39.56 |
$7.42 |
5.33 |
| 2013-03-31 |
37.76 |
$6.82 |
5.54 |
| 2012-12-31 |
28.34 |
$6.28 |
4.51 |
| 2012-09-30 |
25.59 |
$5.77 |
4.43 |
| 2012-06-30 |
19.78 |
$5.35 |
3.70 |
| 2012-03-31 |
18.85 |
$4.86 |
3.88 |
| 2011-12-31 |
15.79 |
$4.56 |
3.46 |
| 2011-09-30 |
14.97 |
$4.12 |
3.63 |
| 2011-06-30 |
15.98 |
$4.00 |
3.99 |
| 2011-03-31 |
16.39 |
$3.90 |
4.20 |
| 2010-12-31 |
13.98 |
$3.82 |
3.66 |
| 2010-09-30 |
13.74 |
$3.60 |
3.81 |
| 2010-06-30 |
13.23 |
$3.90 |
3.39 |
| 2010-03-31 |
17.54 |
$4.16 |
4.22 |
| 2009-12-31 |
16.69 |
$3.62 |
4.62 |
| 2009-09-30 |
17.94 |
$3.19 |
5.63 |
| 2009-06-30 |
18.07 |
$2.94 |
6.15 |
| 2009-03-31 |
17.87 |
$2.77 |
6.46 |
| 2017-06-30 |
57.42 |
$17.68 |
3.25 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$104.880B |
$27.305B |
|
Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya, Odefsey, Descovy, Biktarvy and Truvada. The portfolio also includes hepatitis C virus drugs like Harvoni and Epclusa and HBV drug. The first cell therapy approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, has diversified Gilead's portfolio. Tecartus, another CAR T-cell therapy, was granted an accelerated approval in the United States for the treatment of relapsed or refractory mantle cell lymphoma. The company is also working on diversifying and growing its business beyond antivirals into other therapeutic areas. Gilead is also making inroads in the oncology space with strategic collaborations and acquisitions.
|
